Date: 2015-12-21
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Astellas Pharma (Japan) Agensys (USA - CA)
Product: AGS-16C3F
Action
mechanism: antibody drug conjugate. AGS-16C3F is an antibody-drug conjugate (ADC) containing a fully human monoclonal antibody (AGS-16C) directed to the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3), conjugated via a non-cleavable linker to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, that has potential antineoplastic activity.
Disease: metastatic renal cell carcinoma (mRCC)
Therapeutic area: Cancer - Oncology
Country: Canada, USA
Trial
details: The purpose of this study is to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma. (NCT02639182)
Latest
news: * On December 21, 2015, a Phase 2 trial sponsored by Astellas Pharma and Agensys was published on the NIH website ClinicalTrials.gov for AGS-16C3F and is currently recruiting participants.
